bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions ...

Bluebird’s lead CAR-T cancer cell therapy idecabtagene vicleucel (ide-cel) was last year hit with an FDA refuse-to-file letter, which required additional data on chemistry, manufacturing and ...

Bluebird bio to be acquired by Carlyle Group & SK Capital, offering up to $9.84/share based on product performance. Former Mirati CEO David Meek set to lead bluebird post-acquisition, with deal ...

For a full version of this story, visit STAT. Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $ ...

In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises "substantial doubt" about its ability to continue as a going concern.

Explore bluebird bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for BLUE. bluebird bio agrees to be acquired by Carlyle Group and SK Capital ...

According to the average brokerage recommendation (ABR), one should invest in Blue Bird (BLBD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts ...

Florida students will be breathing a bit easier this year thanks to the deployment of 13 new Blue Bird electric school buses — some of which will be replacing diesel buses that have been service ...